<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485287</url>
  </required_header>
  <id_info>
    <org_study_id>MP-17</org_study_id>
    <nct_id>NCT03485287</nct_id>
  </id_info>
  <brief_title>Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD</brief_title>
  <official_title>An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Multidisciplinary Association for Psychedelic Studies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Multidisciplinary Association for Psychedelic Studies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-site, open-label, Phase 2, lead-in study assesses the safety and effect of
      3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in participants diagnosed
      with at least severe posttraumatic stress disorder (PTSD). Therapy teams that have been
      identified and trained to work on the sponsor's planned Phase 3 studies will treat at least
      one open-label participant in this study. The study will be conducted in up to N=5
      participants. A flexible dose of MDMA, followed by a supplemental half-dose unless
      contraindicated, is administered during the Treatment Period with manualized psychotherapy in
      three open-label monthly Experimental Sessions. This ~12-week Treatment Period is preceded by
      three Preparatory Sessions. During the Treatment Period, each Experimental Session is
      followed by three Integrative Sessions of non-drug psychotherapy. The Primary Outcome
      measure, the change in Clinician Administered PTSD Scale for DSM 5 (CAPS-5) from Baseline.
      Exploratory measures will address specific symptoms, such as sleep quality, or behavior that
      is sometimes related to PTSD. Drug safety will be assessed by measuring blood pressure, heart
      rate and body temperature during experimental sessions, collecting adverse events and
      measuring suicidal thoughts or behaviors with the Columbia Suicide Severity Rating Scale
      (CSSRS). This study will compare the effects of three open-label manualized Experimental
      Sessions of psychotherapy assisted by flexible doses of MDMA. Initial doses per Experimental
      Session include 100 mg or 125 mg of MDMA compounded with lactose, followed 1.5 to 2 hours
      later by a supplemental half-dose (50 mg or 62.5 mg). Total amounts of MDMA to be
      administered per Experimental Session range from 100 mg to 187.5 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PTSD is a serious debilitating disorder that negatively impacts a person's daily life. PTSD
      is a stress-related psychiatric condition that may occur following a traumatic event such as
      war, disaster, sexual abuse, violence, terrorism, and accidents. PTSD negatively impacts a
      person's daily life, resulting in relationship difficulties, difficulty in finding and
      maintaining a job, reduced cognitive and psychosocial functioning, substance abuse, high-cost
      healthcare use, and increased depression and suicide risk. Available PTSD treatments,
      including medications and therapy, effectively treat only a fraction of people who try them
      for adequate dose and duration. People with PTSD can be treated with psychotherapies and
      pharmacotherapies. In the past decade, there has been a growing amount of research into
      medications and other methods that may augment the effectiveness of psychotherapy for PTSD

      3,4-methylenedioxymethamphetamine is a drug that releases serotonin, norepinephrine and
      dopamine in the brain and indirectly increases levels of the neurohormones oxytocin, arginine
      vasopressin and cortisol. The combined neurobiological effects of MDMA increase compassion,
      reduce defenses and fear of emotional injury, and enhance communication and introspection.
      MDMA produces anxiolytic and prosocial effects, which counteract avoidance and hyperarousal
      in the context of therapy. A combined treatment of MDMA and psychotherapy may be especially
      useful for treating PTSD.

      This multi-site, open-label, Phase 2, lead-in study assesses the safety and effect of
      3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in participants diagnosed
      with at least severe posttraumatic stress disorder (PTSD). Therapy teams that have been
      identified and trained to work on the sponsor's planned Phase 3 studies will treat at least
      one open-label participant in this study. The study will be conducted in up to N=5
      participants. A flexible dose of MDMA, followed by a supplemental half-dose unless
      contraindicated, is administered during the Treatment Period with manualized psychotherapy in
      three open-label monthly Experimental Sessions. This ~12-week Treatment Period is preceded by
      three Preparatory Sessions. During the Treatment Period, each Experimental Session is
      followed by three Integrative Sessions of non-drug psychotherapy. The Primary Outcome
      measure, the change in Clinician Administered PTSD Scale for DSM 5 (CAPS-5) from Baseline.
      Exploratory measures will address specific symptoms, such as sleep quality, or behavior that
      is sometimes related to PTSD. Drug safety will be assessed by measuring blood pressure, heart
      rate and body temperature during experimental sessions, collecting adverse events and
      measuring suicidal thoughts or behaviors with the Columbia Suicide Severity Rating Scale
      (CSSRS). This study will compare the effects of three open-label manualized Experimental
      Sessions of psychotherapy assisted by flexible doses of MDMA. Initial doses per Experimental
      Session include 100 mg or 125 mg of MDMA compounded with lactose, followed 1.5 to 2 hours
      later by a supplemental half-dose (50 mg or 62.5 mg). Total amounts of MDMA to be
      administered per Experimental Session range from 100 mg to 187.5 mg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label multi-site study axamining safety and effects of three sessions of MDMA-assisted psychotherapy, with Clinician-Administered PTSD Scale for DSM 5 (CAPS-5) severity after treatment compared with baseline</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS 5)</measure>
    <time_frame>18 weeks post enrollment</time_frame>
    <description>Global severity Scores on the CAPS-5, a measure of PTSD symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Beck Depression Inventory - II (BDI-II)</measure>
    <time_frame>18 weeks post-enrollment</time_frame>
    <description>Score assesses self-reported symptoms of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood pressure (SBP</measure>
    <time_frame>Seven weeks after enrollment</time_frame>
    <description>Systolic blood pressure assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood pressure (SBP</measure>
    <time_frame>Eleven (11) weeks after enrollment</time_frame>
    <description>Systolic blood pressure assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood pressure (SBP</measure>
    <time_frame>15 weeks after enrollment</time_frame>
    <description>Systolic blood pressure assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure (DBP</measure>
    <time_frame>Seven weeks after enrollment</time_frame>
    <description>Diastolic blood pressure assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure (DBP</measure>
    <time_frame>Eleven (11) weeks after enrollment</time_frame>
    <description>Diastolic blood pressure assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure (DBP</measure>
    <time_frame>15 weeks after enrollment</time_frame>
    <description>Diastolic blood pressure assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Seven weeks after enrollment</time_frame>
    <description>Pulse assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Eleven (11) weeks after enrollment</time_frame>
    <description>Pulse assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>15 weeks after enrollment</time_frame>
    <description>Pulse assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>Seven weeks after enrollment</time_frame>
    <description>Body temperature assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>Eleven (11) weeks after enrollment</time_frame>
    <description>Body temperature assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>15 weeks after enrollment</time_frame>
    <description>Body temperature assessed 1.5 to 2 hours after initial MDMA dose</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>MDMA and Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDMA</intervention_name>
    <description>Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later</description>
    <arm_group_label>MDMA and Psychotherapy</arm_group_label>
    <other_name>3,4-methylenedioxymethamphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychotherapy</intervention_name>
    <description>Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session</description>
    <arm_group_label>MDMA and Psychotherapy</arm_group_label>
    <other_name>MDMA-assisted psychotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are at least 18 years old

          -  Are fluent in speaking and reading the predominantly used or recognized language of
             the study site

          -  Agree to have study visits recorded, including Experimental Sessions, Independent
             Rater assessments, and non-drug psychotherapy sessions

          -  Must provide a contact (relative, spouse, close friend or other caregiver) who is
             willing and able to be reached by the investigators in the event of a participant
             becoming suicidal or unreachable.

          -  Must agree to inform the investigators within 48 hours of any medical conditions and
             procedures.

          -  If of childbearing potential, must have a negative pregnancy test at study entry and
             prior to each Experimental Session, and must agree to use adequate birth control
             through 10 days after the last Experimental Session.

          -  Must not participate in any other interventional clinical trials during the duration
             of the study,

          -  Must be willing to remain overnight at the study site after each Experimental Session
             and be driven home after, and commit to medication dosing, therapy, and study
             procedures

        Exclusion Criteria:

          -  Are not able to give adequate informed consent

          -  Have uncontrolled hypertension

          -  Have a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration
             of a QTc interval &gt;450 milliseconds [ms] corrected by Bazett's formula)

          -  Have a history of additional risk factors for Torsade de pointes (e.g., heart failure,
             hypokalemia, family history of Long QT Syndrome)

          -  Have evidence or history of significant medical disorders

          -  Have symptomatic liver disease

          -  Have history of hyponatremia or hyperthermia

          -  Weigh less than 48 kilograms (kg)

          -  Are pregnant or nursing, or are of childbearing potential and are not practicing an
             effective means of birth control.

          -  Must not be abusing illegal drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Mithoefer</last_name>
    <role>Study Director</role>
    <affiliation>MAPS Public Benefit Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Centre on Substance Abuse</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V64 1H</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Study coordinator</last_name>
      <phone>(604)360-1850</phone>
      <email>maps.trial.bc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Keith Ahamad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Simon Amar, LLC</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H2W 1Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Simon Amar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>MDMA</keyword>
  <keyword>Psychotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share outcome data appearing in any published reports upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

